The performance of Carbohydrate Antigen 125-Thomsen-nouveau and anti-Müllerian hormone combined with CA125, Human epididymis protein 4 and Risk of Malignancy Algorithm in diagnosis for patients with Epithelial ovarian cancer

• Published in: Clinical biochemistry Vol. 119; p. 110615
• Main Authors: Hou, Xiuzhu, Liu, Shanshan, Liu, Jing, Zhou, Jiansuo, Liang, Yongming, Cui, Liyan
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.09.2023
• Subjects: Anti-Müllerian hormone; Carbohydrate Antigen 125; Carbohydrate Antigen 125-Thomsen-nouveau; Epithelial ovarian cancer; Human epididymis protein 4; Risk of Malignancy Algorithm; Carbohydrate Antigen 125; BOT; CI; ROC; CCO; AUC; BET; Anti-Müllerian hormone; Human epididymis protein 4; Epithelial ovarian cancer; HE4; ROMA; EOC; CA125; Carbohydrate Antigen 125-Thomsen-nouveau; Tn; Spearman r; HC; AMH; Risk of Malignancy Algorithm; DC

•CA125-Tn and AMH can be treated as valuable biomarkers of Epithelial ovarian cancer.•ROMA was positively correlated with CA125-Tn and negatively correlated with AMH.•Combined with CA125, HE4 and ROMA, CA125-Tn and AMH are more conducive to the diagnosis of epithelial ovarian cancer. We examined the...